Dyadic International, Inc., a biotechnology company, engages in the discovery, development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic International, Inc. has a research collaboration with Mitsubishi Tanabe Pharma Corporation to explore the potential of its C1 technology to produce two vital therapeutic proteins for human health indications; and the Sanofi-Aventis Deutschland GmbH to explore the potential of its C1 technology to produce various types of biologic vaccines and drugs of interest for human health indications. The company was founded in 1979 and is headquartered in Jupiter, Florida.
Industry, Sector and Symbol
Stock Exchange OTCMKTS
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:DYAI
CUSIPN/A
Phone561-743-8333
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E Ratio-11.06
Forward P/E Ratio-7.23
P/E GrowthN/A
Sales & Book Value
Annual Sales$760,000.00
Price / Sales66.07
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)($0.17)
Net Income$-2,140,000.00
Net Margins-841.68%
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares26,710,000
Market Cap$52.03 million
Dyadic International (OTCMKTS:DYAI) Frequently Asked Questions
What is Dyadic International's stock symbol?
Dyadic International trades on the OTCMKTS under the ticker symbol "DYAI."
How were Dyadic International's earnings last quarter?
Dyadic International, Inc (OTCMKTS:DYAI) announced its quarterly earnings data on Thursday, August, 9th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter. The biotechnology company earned $0.16 million during the quarter. View Dyadic International's Earnings History.
When is Dyadic International's next earnings date?
Who are some of Dyadic International's key competitors?
Some companies that are related to Dyadic International include Anavex Life Sciences (AVXL), HedgePath Pharmaceuticals (HPPI), Luna Innovations (LUNA), Senomyx (SNMX), Vitality Biopharma (VBIO), BIOQUAL (BIOQ), Cleveland BioLabs (CBLI), Bioanalytical Systems (BASI), US Stem Cell (USRM), Protalex (PRTX), Tenax Therapeutics (TENX), Geovax Labs (GOVX), ALGAE TEC LTD/S (ALGXY) and Redpoint Bio (RPBC).
Who are Dyadic International's key executives?
Dyadic International's management team includes the folowing people:
- Mr. Mark A. Emalfarb, Founder, CEO, Pres & Director (Age 62)
- Mr. Thomas L. Dubinski, CFO, VP & Corp. Sec. (leave of absence) (Age 61)
- Mr. Matthew S. Jones, Managing Director of Bus. Devel. & Licensing (Age 40)
- Dr. Ronen Tchelet, VP of Research & Bus. Devel. (Age 60)
- Ms. Ping W. Rawson, Chief Accounting Officer & Principal Financial Officer
How do I buy shares of Dyadic International?
Shares of DYAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dyadic International's stock price today?
One share of DYAI stock can currently be purchased for approximately $1.88.
How big of a company is Dyadic International?
Dyadic International has a market capitalization of $52.03 million and generates $760,000.00 in revenue each year. The biotechnology company earns $-2,140,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis.
What is Dyadic International's official website?
How can I contact Dyadic International?
Dyadic International's mailing address is 140 Intracoastal Pointe Drive Suite 404, Jupiter FL, 33477-5094. The biotechnology company can be reached via phone at 561-743-8333 or via email at [email protected]
MarketBeat Community Rating for Dyadic International (OTCMKTS DYAI)
MarketBeat's community ratings are surveys of what our community members think about Dyadic International and other stocks. Vote "Outperform" if you believe DYAI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DYAI will underperform the S&P 500 over the long term. You may vote once every thirty days.
